- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04507555
Pharmacist Guided Pre-emptive Pharmacogenetic Testing in Antidepressant Therapy (PrePGx)
Study Overview
Status
Conditions
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Céline Stäuble, MSc
- Phone Number: +41 61 207 61 78
- Email: celine.staeuble@unibas.ch
Study Locations
-
-
-
Solothurn, Switzerland, 4503
- Recruiting
- Psychiatrische Dienste Solothurn
-
Contact:
- Thorsten Mikoteit, PD Dr. med.
- Phone Number: +41 32 627 11 11
- Email: thorsten.mikoteit@spital.so.ch
-
-
Bern
-
Münchenbuchsee, Bern, Switzerland, 3053
- Recruiting
- Privatklinik Wyss
-
Contact:
- Christian Imboden, Dr. med.
- Phone Number: +4131 868 33 33
- Email: info@privatklinik-wyss.ch
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- ≥ 18 years old
- Diagnosis unipolar moderate or severe depressive episode or recurrent depressive disorder (ICD10: F32.1/32.2/33.1/33.2)
- HAM-D17 ≥ 17
Exclusion Criteria:
- Acute suicide risk
- Psychotic symptomatology
- Other acute serious psychiatric disorder other than depression
- Excessive consumption of alcohol and/or drugs
- Severe acute - or severe chronic somatic diseases
- Pregnant / lactating women
- Under current treatment with fluoxetine
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention
|
The study intervention is the service of pharmacist guided pre-emptive PGx testing to support clinical decision making for antidepressant selection and dosing. This service involves genotyping and thereof evidence-based genotype interpretation commercially offered as Stratipharm® (humatrix AG, Pfungstadt Germany, https://www.stratipharm.de). Furthermore, clinical pharmacists will process and evaluate the results from PGx testing (Stratipharm®) in context of the individual patient medication history as well as current co-medication and forward an individualized recommendation for antidepressant selection and dosing to the treating psychiatrist. |
Active Comparator: Standard Care
|
Selection and dosing of the new antidepressant pharmacotherapy will be determined by the treating investigator alone, according to current standard of care considering clinical factors only.
|
No Intervention: Observational
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
rate of response to the antidepressant therapy at the end of week 4
Time Frame: 28 days
|
response is determined as a reduction in the Hamilton Depression (HAM-D17) Scale score of at least 50 % of the baseline value
|
28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to response
Time Frame: 28 days
|
time span from start of antidepressant pharmacotherapy until first assessed response (= HAM-D17 reduction of at least 50 % compared to baseline
|
28 days
|
Remission rate
Time Frame: 28 days
|
17 item Hamilton rating scale for Depression (HAM-D17) score ≤ 8
|
28 days
|
Overall change in 17 item Hamilton rating scale for Depression (HAM-D17) from baseline to week 4
Time Frame: 28 days
|
minimum value: 0, maximum value: 52 ; higher scores mean worse outcome
|
28 days
|
Time till discharge
Time Frame: assessed up to 3 month
|
time span from admission (randomization) to discharge from inpatient treatment
|
assessed up to 3 month
|
Patient depression self-rating
Time Frame: 28 days
|
two weekly assessment with Beck's Depression Inventory questionnaire (BDI-II)
|
28 days
|
Side effect measure (self-rated frequency, intensity and burden of side effects, FIBSER score)
Time Frame: 28 days
|
weekly assessment, minimum value: 0, maximum value: 18 ; higher scores mean worse outcome
|
28 days
|
Number of adverse events related to antidepressant pharmacotherapy
Time Frame: 28 days
|
severity grading ≥ 2 (using CTCAE version 5.0) and causality to antidepressant pharmacotherapy assessed as possible, probable or definite
|
28 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Thorsten Mikoteit, PD Dr. med., Psychiatrische Dienste Solothurn
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PrePGx_ex20Mikoteit
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Northern Illinois UniversityUniversity Autonoma de Santo DomingoTerminatedDepression Moderate | Depression MildUnited States, Dominican Republic
-
Gerbera Therapeutics, Inc.Not yet recruitingPostpartum Depression | Depression, Postpartum | Postnatal Depression | Post-partum Depression | Post-Natal DepressionUnited States
Clinical Trials on Pharmacist-guided pharmacogenetic (PGx) testing for antidepressant selection and dosing
-
Medstar Health Research InstituteKailos Genetics, Inc.Active, not recruitingChronic PainUnited States
-
Intermountain Health Care, Inc.CompletedThromboembolismUnited States
-
University of PennsylvaniaActive, not recruitingAcute Pain | Post Operative PainUnited States